Last 7 days
20.3%
Last 30 days
13.6%
Last 90 days
-47.2%
Trailing 12 Months
-81.7%
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 150.7M | 162.9M | 169.9M | 0 |
2022 | 107.4M | 114.2M | 126.8M | 138.6M |
2021 | 78.3M | 89.7M | 94.3M | 101.5M |
2020 | 69.5M | 69.7M | 72.7M | 75.2M |
2019 | 41.6M | 48.8M | 56.2M | 63.4M |
2018 | 22.8M | 26.9M | 30.8M | 34.6M |
2017 | 0 | 0 | 0 | 14.3M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Nov 02, 2023 | mckhann chas | acquired | - | - | 612,083 | chief executive officer |
Oct 27, 2023 | jones marie l. | sold | -4,334 | 6.607 | -656 | cao and vp, finance |
Oct 04, 2023 | buchanan lucas w. | sold | -40,523 | 15.223 | -2,662 | coo/cfo |
Sep 15, 2023 | klemz kevin m | acquired | - | - | 86,076 | evp/chief legal officer/sec. |
Sep 15, 2023 | davis andrew s. | acquired | - | - | 121,519 | chief commercial officer |
Sep 15, 2023 | buchanan lucas w. | acquired | - | - | 222,785 | coo/cfo |
Sep 15, 2023 | ruedy richard | acquired | - | - | 28,354 | evpclin®.affairs&qa |
Sep 15, 2023 | jones marie l. | acquired | - | - | 7,595 | cao and vp, finance |
Aug 17, 2023 | klemz kevin m | sold | -30,941 | 20.105 | -1,539 | evp/chief legal officer/sec. |
Aug 03, 2023 | davis andrew s. | sold | -145,797 | 22.134 | -6,587 | chief commercial officer |
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Nov 24, 2023 | DEUTSCHE BANK AG\ | reduced | -93.5 | -10,639,600 | 328,806 | -% |
Nov 22, 2023 | Graham Capital Management, L.P. | new | - | 298,915 | 298,915 | 0.01% |
Nov 21, 2023 | Walleye Capital LLC | new | - | 213,308 | 213,308 | -% |
Nov 21, 2023 | COMERICA BANK | new | - | 9,402 | 9,402 | -% |
Nov 17, 2023 | TimesSquare Capital Management, LLC | sold off | -100 | -12,259,000 | - | -% |
Nov 16, 2023 | Financial Gravity Asset Management, Inc. | sold off | -100 | -61.00 | - | -% |
Nov 15, 2023 | JANE STREET GROUP, LLC | added | 215 | 222,865 | 713,659 | -% |
Nov 15, 2023 | Bullseye Asset Management LLC | added | 39.82 | -921,000 | 1,675,000 | 0.93% |
Nov 15, 2023 | Tudor Investment Corp Et Al | added | 384 | 541,896 | 980,316 | 0.01% |
Nov 15, 2023 | iA Global Asset Management Inc. | sold off | -100 | -1,974,000 | - | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Oct 20, 2023 | flynn james e | 0.00% | 0 | SC 13G | |
Aug 10, 2023 | alliancebernstein l.p. | 0.1% | 46,800 | SC 13G/A | |
May 10, 2023 | wasatch advisors lp | - | 0 | SC 13G/A | |
Feb 14, 2023 | alliancebernstein l.p. | 6.9% | 2,616,795 | SC 13G/A | |
Feb 13, 2023 | capital world investors | 7.8% | 2,966,730 | SC 13G/A | |
Feb 10, 2023 | flynn james e | 3.66% | 1,396,640 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 9.34% | 3,562,110 | SC 13G/A | |
Feb 08, 2023 | wasatch advisors inc | - | 0 | SC 13G/A | |
Jan 31, 2023 | blackrock inc. | 7.0% | 2,664,762 | SC 13G/A | |
Apr 11, 2022 | alliancebernstein l.p. | 10.7% | 3,747,528 | SC 13G/A |
Date Filed | Form Type | Document | |
---|---|---|---|
Nov 08, 2023 | 10-Q | Quarterly Report | |
Nov 08, 2023 | 8-K | Current Report | |
Nov 06, 2023 | 144 | Notice of Insider Sale Intent | |
Nov 03, 2023 | 3 | Insider Trading | |
Nov 03, 2023 | 4 | Insider Trading | |
Nov 02, 2023 | 8-K | Current Report | |
Oct 30, 2023 | 4 | Insider Trading | |
Oct 20, 2023 | SC 13G | Major Ownership Report | |
Oct 10, 2023 | 8-K | Current Report | |
Oct 06, 2023 | 4 | Insider Trading |
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
ABT | 183.0B | 40.0B | 9.73% | -2.70% | 35.46 | 4.58 | -11.26% | -34.57% |
BDX | 71.3B | 19.4B | -8.25% | -5.16% | 44.09 | 3.79 | 2.66% | -16.58% |
BAX | 18.7B | 15.0B | 8.63% | -30.19% | 7.2 | 1.24 | 3.01% | 209.09% |
ALGN | 16.8B | 3.8B | 11.22% | 10.68% | 46.36 | 4.42 | -1.48% | -28.97% |
MID-CAP | ||||||||
HSIC | 9.0B | 12.7B | 11.09% | -16.77% | 20.24 | 0.71 | 0.68% | -30.25% |
BIO | 9.0B | 2.7B | 7.31% | -26.28% | -56.42 | 3.3 | -3.01% | 97.36% |
ATR | 8.4B | 3.4B | 2.45% | 18.85% | 30.02 | 2.45 | 3.13% | 18.17% |
XRAY | 6.9B | 3.9B | 12.08% | 3.35% | -31.81 | 1.76 | -2.62% | 73.28% |
AXNX | 2.9B | 342.6M | 6.85% | -17.46% | -245.59 | 8.59 | 42.19% | 84.14% |
PDCO | 2.5B | 6.6B | -16.25% | -11.02% | 12.27 | 0.37 | 2.61% | 0.62% |
SMALL-CAP | ||||||||
AHCO | 1.2B | 3.1B | 8.50% | -59.80% | -2.91 | 0.4 | 7.95% | -550.16% |
ANIK | 333.0M | 163.3M | 7.72% | -27.92% | -13.55 | 2.04 | 7.14% | -56.09% |
ANGO | 271.9M | 335.9M | -0.73% | -44.59% | 42.18 | 0.81 | 4.71% | 116.39% |
APYX | 74.8M | 50.3M | -17.56% | 18.68% | -4.94 | 1.49 | 3.23% | 20.81% |
AEMD | 5.1M | 3.8M | 9.63% | -51.71% | -0.44 | 1.34 | 17.30% | 10.67% |
Income Statement (Quarterly) | (In Thousands) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
Revenue | -1.9% | 44,435,000 | 45,298,000 | 40,131,000 | 40,071,000 | 37,374,000 | 33,173,000 | 28,021,000 | 28,265,000 | 24,701,000 | 26,456,000 | 22,053,000 | 21,133,000 | 20,067,000 | 15,094,000 | 18,933,000 | 18,634,000 | 17,026,000 | 14,928,000 | 12,766,000 | 11,470,000 | 9,614,000 |
Gross Profit | 0.3% | 32,385,000 | 32,294,000 | 27,605,000 | 29,092,000 | 28,066,000 | 24,161,000 | 19,444,000 | 21,032,000 | 18,625,000 | 19,858,000 | 16,515,000 | 15,916,000 | 14,579,000 | 9,758,000 | 13,683,000 | 13,913,000 | 12,856,000 | 11,231,000 | 9,427,000 | 7,803,000 | 6,732,000 |
Operating Expenses | -1.2% | 46,056,000 | 46,610,000 | 44,515,000 | 41,722,000 | 37,292,000 | 38,355,000 | 35,398,000 | 35,094,000 | 31,916,000 | 29,810,000 | 26,678,000 | 30,911,000 | 23,913,000 | 19,151,000 | 22,823,000 | 21,420,000 | 20,251,000 | 17,248,000 | 16,573,000 | 15,102,000 | 11,415,000 |
S&GA Expenses | 0.5% | 36,009,000 | 35,830,000 | 34,082,000 | 32,522,000 | 28,821,000 | 27,700,000 | 27,275,000 | 27,595,000 | 25,049,000 | 22,549,000 | 21,194,000 | 20,872,000 | 19,202,000 | 15,758,000 | 19,692,000 | 18,156,000 | 17,064,000 | 14,135,000 | 13,866,000 | 11,712,000 | 8,973,000 |
R&D Expenses | -6.8% | 10,047,000 | 10,780,000 | 10,433,000 | 9,200,000 | 8,471,000 | 10,655,000 | 8,123,000 | 7,499,000 | 6,867,000 | 7,261,000 | 5,484,000 | 10,039,000 | 4,711,000 | 3,393,000 | 3,131,000 | 3,264,000 | 3,187,000 | 3,113,000 | 2,707,000 | 3,390,000 | 2,442,000 |
EBITDA Margin | - | - | - | - | - | - | -0.41 | -0.44 | -0.47 | - | - | -0.55 | -0.56 | -0.64 | -0.67 | -0.67 | -0.74 | -0.57 | -0.66 | -0.78 | - | - |
Interest Expenses | 1.2% | 1,732,000 | 1,712,000 | 1,693,000 | 1,732,000 | 1,714,000 | 1,031,000 | 621,000 | 634,000 | 633,000 | 628,000 | 623,000 | 791,000 | 1,215,000 | 1,203,000 | 1,202,000 | 1,216,000 | 1,176,000 | 1,207,000 | 1,352,000 | 1,296,000 | 1,065,000 |
EBT Margin | - | - | - | - | - | - | -0.44 | -0.46 | -0.49 | - | - | -0.60 | -0.63 | -0.72 | -0.75 | -0.75 | -0.83 | -0.67 | -0.77 | -0.90 | - | - |
Net Income | 5.2% | -12,788,000 | -13,484,000 | -16,460,000 | -12,614,000 | -10,319,000 | -15,398,000 | -16,679,000 | -14,693,000 | -13,885,000 | -10,539,000 | -10,694,000 | -16,756,000 | -10,315,000 | -10,353,000 | -9,941,000 | -8,291,000 | -8,007,000 | -11,959,000 | -24,158,000 | -15,618,000 | -8,953,000 |
Net Income Margin | - | - | - | -0.36 | -0.40 | -0.45 | -0.53 | -0.52 | -0.49 | -0.55 | -0.54 | -0.61 | -0.63 | -0.53 | -0.53 | -0.55 | -0.83 | - | - | - | - | - |
Free Cashflow | - | - | - | -12,434,000 | -4,291,000 | -5,115,000 | -11,383,000 | -16,797,000 | -14,184,000 | -7,627,000 | -9,843,000 | -12,039,000 | -14,524,000 | -4,531,000 | -11,926,000 | -11,929,000 | -5,459,000 | - | - | - | - | - |
Balance Sheet | (In Millions) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2017Q4 |
Assets | -0.9% | 261 | 263 | 260 | 270 | 163 | 163 | 143 | 157 | 166 | 168 | 170 | 179 | 184 | 188 | 127 | 137 | 139 | 143 | 39.00 | 43.00 | 43.00 |
Current Assets | 3.2% | 241 | 233 | 230 | 255 | 147 | 147 | 128 | 143 | 154 | 159 | 164 | 173 | 178 | 181 | 120 | 112 | 132 | 136 | 29.00 | 39.00 | 42.00 |
Cash Equivalents | 2.8% | 29.00 | 28.00 | 50.00 | 55.00 | 51.00 | 88.00 | 94.00 | 110 | 106 | 102 | 95.00 | 70.00 | 63.00 | 74.00 | 28.00 | 39.00 | 113 | 119 | 16.00 | 25.00 | 34.00 |
Inventory | 15.7% | 22.00 | 19.00 | 17.00 | 19.00 | 20.00 | 18.00 | 18.00 | 18.00 | 16.00 | 13.00 | 12.00 | 10.00 | 11.00 | 12.00 | 12.00 | 10.00 | 9.00 | 9.00 | 8.00 | 6.00 | 3.00 |
Net PPE | -3.6% | 8.00 | 9.00 | 9.00 | 9.00 | 10.00 | 10.00 | 10.00 | 8.00 | 5.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 0.00 |
Liabilities | -0.1% | 108 | 108 | 102 | 106 | 105 | 103 | 75.00 | 77.00 | 77.00 | 72.00 | 69.00 | 72.00 | 64.00 | 60.00 | 63.00 | 66.00 | 61.00 | 58.00 | 91.00 | 72.00 | 36.00 |
Current Liabilities | -0.3% | 24.00 | 24.00 | 21.00 | 24.00 | 24.00 | 21.00 | 29.00 | 26.00 | 21.00 | 17.00 | 16.00 | 20.00 | 15.00 | 12.00 | 14.00 | 17.00 | 12.00 | 9.00 | 11.00 | 11.00 | 5.00 |
Short Term Borrowings | - | - | - | - | - | - | - | 10.00 | 4.00 | - | - | - | - | - | - | - | - | - | - | - | - | - |
LT Debt, Non Current | 0.3% | 75.00 | 75.00 | 75.00 | 75.00 | 74.00 | 74.00 | 39.00 | 45.00 | 49.00 | 49.00 | 49.00 | 49.00 | 45.00 | 45.00 | 45.00 | 45.00 | 45.00 | 45.00 | 45.00 | 44.00 | 28.00 |
Shareholder's Equity | -1.5% | 153 | 156 | 158 | 164 | 57.00 | 60.00 | 68.00 | 79.00 | 88.00 | 96.00 | 101 | 108 | 120 | 127 | 64.00 | 72.00 | 77.00 | 84.00 | - | - | - |
Retained Earnings | -3.4% | -386 | -373 | -360 | -343 | -331 | -320 | -305 | -288 | -274 | -260 | -249 | -238 | -222 | -211 | -201 | -191 | -183 | -175 | -163 | -139 | -101 |
Additional Paid-In Capital | 2.0% | 540 | 529 | 518 | 508 | 388 | 381 | 373 | 368 | 362 | 356 | 351 | 346 | 342 | 339 | 265 | 263 | 261 | 260 | 5.00 | 5.00 | 3.00 |
Shares Outstanding | 0.2% | 39.00 | 39.00 | 39.00 | 38.00 | 35.00 | 35.00 | 35.00 | 35.00 | 35.00 | 35.00 | 34.00 | 34.00 | 34.00 | 32.00 | 31.00 | 23.00 | 31.00 | 28.00 | - | 1.00 | 1.00 |
Cashflow (Quarterly) | (In Thousands) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
Cashflow From Operations | -47.3% | -6,798 | -4,616 | -12,147 | -2,724 | -4,726 | -10,406 | -14,725 | -11,432 | -6,495 | -9,036 | -11,972 | -14,269 | -4,423 | -11,581 | -11,795 | -5,261 | -6,346 | -9,383 | -8,620 | -5,390 | -6,367 |
Share Based Compensation | 0.5% | 10,247 | 10,199 | 8,838 | 7,545 | 6,339 | 6,161 | 4,978 | 3,984 | 3,686 | 3,409 | 3,533 | 2,273 | 2,006 | 1,654 | 1,293 | 954 | 924 | 837 | 262 | 226 | 194 |
Cashflow From Investing | 138.9% | 7,456 | -19,158 | 6,106 | -104,951 | -32,895 | -22,150 | -2,072 | 14,250 | 7,968 | 14,193 | 36,233 | 12,898 | -7,386 | -14,797 | -108 | -69,619 | -131 | -89.00 | -117 | -102 | -1,164 |
Cashflow From Financing | -91.8% | 130 | 1,592 | 1,110 | 111,727 | 1,213 | 26,591 | 168 | 1,771 | 2,242 | 2,117 | 848 | 8,369 | 835 | 72,268 | 274 | 1,784 | 507 | 112,210 | -744 | -226 | 15,218 |
Condensed Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Condensed Statements of Operations and Comprehensive Loss [Abstract] | ||||
Revenue | $ 44,435 | $ 37,374 | $ 129,864 | $ 98,567 |
Cost of goods sold | 12,050 | 9,308 | 37,580 | 26,897 |
Gross profit | 32,385 | 28,066 | 92,284 | 71,670 |
Operating expenses: | ||||
Research and development | 10,047 | 8,471 | 31,260 | 27,249 |
Selling, general and administrative | 36,009 | 28,821 | 105,923 | 83,795 |
Total operating expenses | 46,056 | 37,292 | 137,183 | 111,044 |
Loss from operations | (13,671) | (9,226) | (44,899) | (39,374) |
Interest income | 2,617 | 617 | 7,339 | 751 |
Interest expense | (1,732) | (1,714) | (5,137) | (3,366) |
Loss on debt extinguishment | (245) | |||
Other income (expense), net | (2) | 4 | (35) | (162) |
Net loss | (12,788) | (10,319) | (42,732) | (42,396) |
Other comprehensive loss: | ||||
Unrealized gain (loss) on investments, net | 47 | (189) | (118) | (191) |
Other comprehensive loss | 47 | (189) | (118) | (191) |
Net loss and comprehensive loss | $ (12,741) | $ (10,508) | $ (42,850) | $ (42,587) |
Net loss per share, basic | $ (0.33) | $ (0.29) | $ (1.10) | $ (1.21) |
Net loss per share, diluted | $ (0.33) | $ (0.29) | $ (1.10) | $ (1.21) |
Weighted average common shares used to compute net loss per share, basic | 38,865,011 | 35,303,958 | 38,722,012 | 35,157,840 |
Weighted average common shares used to compute net loss per share, diluted | 38,865,011 | 35,303,958 | 38,722,012 | 35,157,840 |
Condensed Balance Sheets - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 29,188 | $ 55,358 |
Short-term investments | 163,673 | 158,316 |
Accounts receivable, net | 21,779 | 18,007 |
Inventories | 22,066 | 19,293 |
Prepaid expenses and other current assets | 4,277 | 3,924 |
Total current assets | 240,983 | 254,898 |
Long-term investments | 4,348 | |
Property and equipment, net | 8,337 | 9,372 |
Restricted cash | 0 | 155 |
Other non-current assets | 7,196 | 5,260 |
Total assets | 260,864 | 269,685 |
Current liabilities: | ||
Accounts payable | 5,094 | 2,523 |
Accrued liabilities | 18,928 | 21,965 |
Total current liabilities | 24,022 | 24,488 |
Long-term debt | 75,364 | 74,596 |
Other liabilities | 8,336 | 6,726 |
Total liabilities | 107,722 | 105,810 |
Commitments and contingencies (Note 7) | ||
Stockholders' equity: | ||
Preferred stock, $0.001 par value Shares authorized: 5,000,000 at September 30, 2023 and December 31, 2022 Shares issued and outstanding: none at September 30, 2023 and December 31, 2022 | ||
Common stock, $0.001 par value Shares authorized: 100,000,000 at September 30, 2023 and December 31, 2022 Shares issued and outstanding: 38,907,789 and 38,355,972 at September 30, 2023 and December 31, 2022, respectively | 39 | 38 |
Additional paid-in capital | 539,831 | 507,715 |
Accumulated other comprehensive loss | (284) | (166) |
Accumulated deficit | (386,444) | (343,712) |
Total stockholders’ equity | 153,142 | 163,875 |
Total liabilities and stockholders’ equity | $ 260,864 | $ 269,685 |
 CEO | Ms. Erica J. Rogers |
---|---|
 WEBSITE | silkroadmed.com |
 EMPLOYEES | 414 |